LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

47e64bcf-896e-4bc0-b4db-413992dc9498articleimage.jpg

29 Sep 2017 --- LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has raised a €6.5 million (US$7.67 million) Series C funding round. This new round, co-led by Seventure Partners, brings together a consortium of investors and a family office. Additionally, the company has appointed a new chief scientific officer, Dr. Sandrine Claus, to lead the gut microbiota project.

“This funding round of €6.5 million establishes LNC Therapeutics as a key player in the treatment of obesity and metabolic disorders through an action on the gut microbiota,” explains Jean-Luc Treillou, LNC therapeutics’ CEO. 

“Our recent clinical trial on obese patients indicated that visceral fat loss in this population was correlated with a modulation of the gut microbiota, specifically with a bacterial family known for its anti-obesity potential,” Treillou adds.

“Hence, our current objective is to develop new drug candidates whose mechanism of action requires interaction with the gut microbiota and the intestinal membrane. Targeted therapeutic indications include pathologies caused by excessive visceral fat accumulation and chronic inflammation such as obesity and NASH.”

“The presentation of our development plan is scheduled in the first quarter of 2018 and will include targets and project milestones,” Caroline Bernard, Strategic Development Project Manager at LNC Therapeutics, tells NutritionInsight.

Regarding the populations LNC Therapeutics intends to target its research on, Bernard adds that LNC will indeed focus on some specific (but still large) sub-populations to maximize clinical outcomes, but did not provide further details on these sub-populations.

Click to EnlargeNew CSO
Newly appointed Chief Scientific Officer Sandrine Claus, Ph.D., is Associate Professor in Integrative Metabolism at the University of Reading, which she joined in 2010. Its research focuses on the host-gut microbial metabolic interactions to link gut microbial ecology to metabolic health.

Claus’ mission within LNC Therapeutics will be leading the ambitious R&D pipeline and the development of new treatments in the field of cardiometabolic diseases and other fields of investigation relating to the bioactivity of some peptides.

“It is with great pleasure that I am joining LNC Therapeutics and its dynamic team. It is an exciting time to join a company which owns a large pipeline of innovative patents related to gut microbiota activity, aimed at improving health outcomes,” comments Sandrine Claus.

“Our new CSO, Dr. Sandrine Claus, Ph.D., who is an expert on the role of gut microbiota in the development of metabolic disorders, is a strategic recruitment. Our strategic plan now has to be delivered and will drive us to an IPO by the end of 2019,” concludes Jean-Luc Treillou.

“We are pleased to participate in this new round and to have syndicated the Series C with other ‘deep pocket’ investors. LNC Therapeutics, a company we have supported since the Series A, chose to remain discreet over the last two years in the booming universe of the microbiome, to gain a foothold and consolidate its competitive position. LNC Therapeutics is complementing our portfolio of microbiome champions, consisting of companies that are advanced in their research,” adds Isabelle de Crémoux, CEO of Seventure Partners and founder of Health For Life Capital.

By Lucy Gunn

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

“Key milestone”: Chr. Hansen trial finds probiotic potential for painkiller gut damage defense

16 May 2018 --- A Chr. Hansen clinical trial has demonstrated the effectiveness of probiotic strains in protecting against potential gut damage caused by the regular use of household painkillers. Chr. Hansen state that they will now focus on fully exploiting the strains full potential, deepening understanding of the underlying mechanisms and gathering sufficient data to publish in a scientific journal. The findings add to a growing research area using probiotics for health.

Food Ingredients News

Probiotics: Scientists investigate how seaweed can give a dietary boost to gut bacteria

11 May 2018 --- US researchers examining how to manipulate gut bacteria to boost essential nutrients for better health have been “blown away” by the results they got when using dietary seaweed in mice.

Nutrition & Health News

Drinks with benefits: Premium organic beverages thriving

11 May 2018 --- Over the past years, the mainstreaming of organic launches has only continued, with Innova Market Insights reporting 20 percent CAGR in organic claims being reported in global food & beverage launches from 2013 to 2017. The mainstreaming of organic foods was a key theme at Natural & Organic Awards Europe, which was held in London at the end of April. Similar to FoodEx 2018 last month, premium beverages touting low sugar content or healthful ingredients, played a key role at the Natural & Organic Awards Europe. 

Nutrition & Health News

Essential oils, kombucha and hemp to take center stage at Vitafoods Europe 2018

10 May 2018 --- Emerging ingredients for health and nutrition will be a key focus at the 2018 edition of Vitafoods Europe which takes place in Palexpo, Geneva next week. A new R&D stream entitled Up and Coming featuring in the event’s Education Program will cater for this revised focus. Notably, essential oils, kombucha and industrial hemp will be in the spotlight.

Nutrition & Health News

Takeda Pharmaceutical takes over Shire in US$62bn deal

08 May 2018 --- Takeda Pharmaceutical has reached a deal to buy Shire Plc. for US$62 billion in a move hoped to rapidly boost Takeda’s global standing as a biopharmaceutical leader. It is predicted to bring together Takeda and Shire’s complementary positions in gastroenterology (GI), neuroscience and more. Also, it may advance Shire’s portfolio with Takeda’s strong presence in emerging markets and Japan.

More Articles
URL : http://www.nutritioninsight.com:80/news/lnc-therapeutics-raises-65m-to-reinforce-its-rd-in-the-microbiota-field.html